medvi compounded semaglutide reviews The Pros and Cons of for Weight Loss MEDVi GLP-1 Review: Hidden Costs

1-2 CT-388 is being investigated as an once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of obesity and type 2 diabetes (T2D)

What the Latest Clinical Trial Results Show According to publicly reported late-stage trial data: Participants receiving higher doses achieved average weight loss approaching 2530% over approximately 68 weeks Some individuals lost more than 70 pounds during the study period Participants with obesity and knee osteoarthritis also reported significant reductions in joint pain These outcomes exceeded the average weight loss typically reported in clinical trials of currently approved GLP-1 medications

If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255)

Diabetologia 62:316

However, much more research is needed in this area before we can draw firm conclusions or incorporate GLP-1 therapy routinely into male fertility care